Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.jubilantpharmova.com | |
Market Cap | 4,482.97 Cr. | |
Enterprise Value(EV) | 6,856.05 Cr. | 2022-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 6.05 | Trailing Twelve Months Ending 2022-12 |
Price-Earning Ratio (PE) | 46.50 | Trailing Twelve Months Ending 2022-12 |
Industry PE | 31.87 | Trailing Twelve Months Ending 2022-12 |
Book Value / Share | 342.86 | Trailing Twelve Months Ending 2022-12 |
Price to Book Value | 0.82 | Calculated using Price: 281.45 |
Dividend Yield | 1.78 | Period Ending 2022-03 |
No. of Shares Subscribed | 15.93 Cr. | 159,281,139 Shares |
FaceValue | 1 | |
Company Profile | ||
Jubilant Life Sciences is an integrated global pharmaceutical and life sciences company engaged in pharmaceuticals, life science ingredients, drug discovery solutions and India branded pharmaceuticals. Jubilant Pharma Limited, is engaged in manufacturing and supply of APIs, solid dosage formulations, radiopharmaceuticals, allergy therapy products and contract manufacturing of sterile injectables and non-sterile products through six USFDA approved manufacturing facilities in the US, Canada and India and a network of various radiopharmacies in the US. |
1 Day |
|
-3.02% |
1 Week |
|
-10.04% |
1 Month |
|
-10.61% |
3 Month |
|
-24.51% |
6 Month |
|
-16.16% |
1 Year |
|
-35.36% |
2 Year |
|
-58.53% |
5 Year |
|
-65.51% |
10 Year |
|
+76.13% |
9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | 5.39 | -1.58 | 14.27 | 17.95 | 16.87 | 12.97 | 13.02 | 10.88 | 8.41 | |
Return on Capital Employed (%) | 7.92 | 5.72 | 12.42 | 14.44 | 15.21 | 13.06 | 12.20 | 11.89 | 10.09 | |
Return on Assets (%) | 1.60 | -0.46 | 4.46 | 6.52 | 6.91 | 5.55 | 5.74 | 5.34 | 4.55 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
Shh. Funds | 2,627 | 2,454 | 2,966 | 3,436 | 4,087 | 4,809 | 5,604 | 4,741 | 5,319 | 5,476 | |
Non Curr. Liab. | 2,185 | 4,036 | 3,347 | 3,826 | 3,417 | 4,420 | 4,088 | 2,973 | 2,922 | 3,524 | |
Curr. Liab. | 3,894 | 2,129 | 2,464 | 1,684 | 2,005 | 2,090 | 2,619 | 1,049 | 1,592 | 1,491 | |
Minority Int. | 158 | -38 | -47 | -52 | 0 | 0 | -2 | -4 | |||
Equity & Liab. | 8,864 | 8,619 | 8,740 | 8,899 | 9,457 | 11,319 | 12,310 | 8,763 | 9,830 | 10,486 | |
Non Curr. Assets | 5,936 | 5,904 | 5,864 | 5,951 | 6,267 | 6,734 | 7,272 | 5,811 | 6,320 | 6,866 | |
Curr. Assets | 2,928 | 2,715 | 2,875 | 2,948 | 3,190 | 4,585 | 5,038 | 2,953 | 3,509 | 3,620 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 8,864 | 8,619 | 8,740 | 8,899 | 9,457 | 11,319 | 12,310 | 8,763 | 9,830 | 10,486 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-12 Rs. Cr. TTM |
Net Sales | 5,803 | 5,826 | 5,749 | 5,861 | 7,518 | 9,111 | 5,976 | 6,099 | 6,130 | 6,131 | |
Other Income | 19 | 42 | 13 | 25 | 40 | 36 | 37 | 18 | 11 | 31 | |
Total Income | 5,822 | 5,869 | 5,763 | 5,886 | 7,558 | 9,147 | 6,013 | 6,116 | 6,141 | 6,162 | |
Total Expenditure | -4,782 | -5,125 | -4,502 | -4,516 | -5,999 | -7,372 | -4,428 | -4,702 | -4,974 | -5,327 | |
PBIDT | 1,040 | 744 | 1,260 | 1,370 | 1,558 | 1,775 | 1,585 | 1,414 | 1,168 | 835 | |
Interest | -337 | -368 | -371 | -341 | -284 | -220 | -200 | -184 | -145 | -172 | |
Depreciation | -281 | -288 | -347 | -291 | -415 | -371 | -340 | -349 | -382 | -383 | |
Taxation | -70 | -80 | -155 | -163 | -225 | -327 | -335 | -297 | -217 | -125 | |
Exceptional Items | -214 | -48 | -280 | -33 | -21 | -57 | |||||
PAT | 138 | -40 | 387 | 575 | 634 | 577 | 678 | 563 | 423 | 98 | |
Minority Interest | -29 | -18 | 5 | 1 | 8 | -3 | 0 | 1 | 2 | ||
Share Associate | 11 | -10 | -3 | ||||||||
Other Related Items | |||||||||||
Consolidated Net Profit | 109 | -58 | 392 | 576 | 643 | 574 | 898 | 836 | 414 | 96 | |
Adjusted EPS | 7 | -4 | 25 | 37 | 41 | 36 | 56 | 53 | 26 | 6 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | 970 | 772 | 783 | 1,099 | 1,268 | 1,303 | 1,122 | 1,543 | 1,784 | 838 | |
Cash Fr. Inv. | -500 | -174 | -343 | -313 | -450 | -618 | -1,012 | -327 | -739 | -380 | |
Cash Fr. Finan. | -450 | -414 | -503 | -843 | -686 | -901 | 657 | -1,050 | -1,709 | -33 | |
Net Change | 20 | 183 | -63 | -56 | 132 | -216 | 767 | 166 | -664 | 425 | |
Cash & Cash Eqvt | 280 | 473 | 392 | 339 | 456 | 244 | 1,005 | 1,231 | 502 | 984 |
Fri, 24 Mar 2023
Closure of Trading Window Closure of trading window |
Fri, 17 Mar 2023
Additional Loan Facility By Government Of Canada For The Expansion Of CMO Montreal Facility We enclose a communication pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015.We request you to take the same on record. |
Tue, 14 Mar 2023
Announcement under Regulation 30 (LODR)-Newspaper Publication Dear Sirs In continuation of our letter dated March 13 2023 we enclose herewith copies of the advertisements published on March 14 2023 in Mint (All editions-English language) and Hindustan (Hindi language) with respect to the completion of dispatch of notices of Postal Ballot.This is for your information and record. |
Fri, 24 Mar 2023 |
|
|
|
|
|